ADTRINIB
Brand Name: ADTRINIB
Composition: Sorafenib Tablets IP
Quantity: 120 Tablets
Manufacturer/Marketer: ADLEY
Product Description
Medical Info
ADTRINIB is a prescription oncology medication containing Sorafenib (200 mg) per tablet. It belongs to the class of multi-kinase inhibitors, designed to target specific proteins responsible for tumor growth and angiogenesis (the formation of blood vessels that supply the tumor). This targeted therapy is primarily indicated for patients diagnosed with advanced renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), and certain types of differentiated thyroid carcinomas that no longer respond to radioactive iodine treatment. Due to its complex mechanism and potential toxicities, ADTRINIB must be taken exactly as directed under the ongoing supervision of a qualified medical oncologist.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
